FDA accepts Alnylam’s vutrisiran sNDA to treat ATTR-CM

Vutrisiran is an RNAi therapeutic aimed at treating transthyretin amyloidosis with cardiomyopathy. Credit: jesse orrico on Unsplash.



  • FDA accepts Alnylam’s vutrisiran sNDA to treat ATTR-CM